Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 203articles · 30d
- 14+ hour agolatest article
- Aug 16, 2026earliest in window
- 95%with images
- 246avg words
- Medical 150
- Health & Wellness 138
- Health 100
- Science & Technology 46
- Business & Industrial 37
- Economy, Business & Finance 22
- Politics 19
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why two promising heart drugs flopped and what's next
3+ day, 19+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
3+ day, 12+ hour ago (159+ words) The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month. They could also have a chilling effect across the industry. Just before Labor Day, Novartis reported that its cardiac therapy, pelacarsen, failed in a…...
Pharmalittle: We're reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
4+ day, 23+ hour ago (167+ words) Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. FDA names acting heads of drug and vaccine…...
Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
5+ day, 23+ hour ago (369+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Novartis gets multiple sclerosis win with BTK inhibitor
1+ week, 5+ day ago (270+ words) By Elaine Chen and Helen Branswell Good morning. I know this week probably feels extra long as we approach Labor Day weekend, but we will get through it together. President Trump yesterday announced that his administration has made deals with…...
Pharmalittle: We're reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
1+ week, 5+ day ago (258+ words) STAT Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more President Trump has announced the next round of pricing deals with drugmakers Andrew covers the biopharma industry, scientific research, and public health across…...
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
2+ week, 19+ hour ago (141+ words) When AstraZeneca on Friday detailed the failed trial of its drug Wainua in a heart condition known as ATTR-CM, the bad news, according to one school of thought, extended to Alnylam Pharmaceuticals. Some analysts interpreted the study’s miss as a…...
A Novartis drug cut inflammation. Can it improve heart outcomes?
2+ week, 2+ day ago (292+ words) A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study, as experts wait to hear how the company plans to advance the drug as a potential cardiovascular treatment. In the Phase 2 TRANQUILITY study, the drug, pacibekitug,…...
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
2+ week, 3+ day ago (138+ words) AstraZeneca on Friday detailed the surprise failure of a closely watched heart disease clinical trial, laying out how its experimental drug offered no additional benefits for patients who were largely already on another type of medicine — the latest twist in…...
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
2+ week, 2+ day ago (159+ words) Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…...